Clinical Trial: Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
Brief Summary: The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.
Detailed Summary: Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.
Sponsor: University of Arizona
Current Primary Outcome: Determine the incidence rate and calculate the risk of coccidioidomycosis in patients receiving various anti-TNF agents or other biologics, and patients not receiving these agents for their inflammatory arthritis [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- To calculate the incidence density of coccidioidomycosis cases in patients receiving each drug. [ Time Frame: One year ]
- To compare number of disseminated cases of coccidioidomycosis in each group [ Time Frame: One year ]
Original Secondary Outcome: Same as current
Information By: University of Arizona
Dates:
Date Received: November 21, 2008
Date Started: October 2007
Date Completion:
Last Updated: December 11, 2015
Last Verified: December 2015
